ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Research & Development of $4.7 million for Q2 2026, up 16.4% from $4.04 million a year earlier and up 8.3% from the prior quarter.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, ARS Pharmaceuticals' Research & Development came in at $15.23 million, up 5.5% year-over-year; for FY2025, it came in at $13.18 million, down 32.7% from FY2024.
- Research & Development has a five-year compound annual growth rate of -11.7% (FY2020 to FY2025).
- By year, Research & Development came in at $19.58 million in FY2024 (-3.4%), $20.27 million in FY2023 (+10.3%), $18.38 million in FY2022 (-9.4%) and $20.27 million in FY2021 (-17.5%).
- The Q2 2026 figure ranks as the highest quarterly Research & Development since Q2 2024.
- Year over year, Research & Development has now increased in each of the last three quarters, with an average decline of 1.2% over the last eight quarters.
- The high point for year-over-year Research & Development in five years was Q3 2021 (growth of 152.3%); the low point was Q2 2022 (a decline of 75.5%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $4.34 million (Q1 2026), $3.44 million (Q4 2025) and $2.75 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | ARS Pharmaceuticals | 335.94 Mn | 197.54 Mn | 27.61 Mn | 18.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 18.26 Mn |
| Jun 30, 2026 | 4.70 Mn |
| Mar 31, 2026 | 4.34 Mn |
| Dec 31, 2025 | 3.44 Mn |
| Sep 30, 2025 | 2.75 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 2.95 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 6.90 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 3.40 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 7.31 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 4.71 Mn |
| Sep 30, 2022 | 3.89 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | 5.42 Mn |
| Dec 31, 2021 | -25.36 Mn |
API Access
ARS Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=SPRY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "SPRY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=SPRY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();